QS11 acts as an inhibitor of ARFGAP1 (ADP-ribosylation factor GTPase-activating protein 1), with an EC50 of 1.5 μM. QS11 regulates Wnt/β-catenin signaling by interacting with ARF GTPase-activating protein 1 (ARFGAP1) and influences protein trafficking. Additionally, QS11 suppresses the migration of breast cancer cells that overexpress ARFGAP1.

SB-328437 is a non-peptide small molecule, potent and selective antagonist of CCR3 with an IC50 of 4.5 nM. It is important for eosinophil recruitment, a process that is thought to be crucial in the pathology of several inflammatory diseases including asthma, allergic rhinitis, and eczema.

SB-328437 is a non-peptide small molecule, potent and selective antagonist of CCR3 with an IC50 of 4.5 nM. It is important for eosinophil recruitment, a process that is thought to be crucial in the pathology of several inflammatory diseases including asthma, allergic rhinitis, and eczema.

SB-328437 is a non-peptide small molecule, potent and selective antagonist of CCR3 with an IC50 of 4.5 nM. It is important for eosinophil recruitment, a process that is thought to be crucial in the pathology of several inflammatory diseases including asthma, allergic rhinitis, and eczema.

Xanomeline(LY-246708) is a selective agonist of muscarinic type 1(M(1) receptor and muscarinic type 4 receptor(M(4). It increases neuronal excitability and inhibits behaviors induced by D-amphetamine and (-)-apomorphine.

Xanomeline(LY-246708) is a selective agonist of muscarinic type 1(M(1) receptor and muscarinic type 4 receptor(M(4). It increases neuronal excitability and inhibits behaviors induced by D-amphetamine and (-)-apomorphine.

SB-328437 is a non-peptide small molecule, potent and selective antagonist of CCR3 with an IC50 of 4.5 nM. It is important for eosinophil recruitment, a process that is thought to be crucial in the pathology of several inflammatory diseases including asthma, allergic rhinitis, and eczema.

BBC0403 is a small-molecule selective inhibitor of Bromodomain-containing protein 2(BRD2) with Kds of 7.64 μM and 41.37 μM for BRD2 (BD2) and BRD2 (BD1), respectively. It is a potential intra-articular injectable therapeutic agent for treating osteoarthritis (OA).

Xanomeline(LY-246708) is a selective agonist of muscarinic type 1(M(1) receptor and muscarinic type 4 receptor(M(4). It increases neuronal excitability and inhibits behaviors induced by D-amphetamine and (-)-apomorphine.

Xanomeline(LY-246708) is a selective agonist of muscarinic type 1(M(1) receptor and muscarinic type 4 receptor(M(4). It increases neuronal excitability and inhibits behaviors induced by D-amphetamine and (-)-apomorphine.